All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076298" target="_blank" >RIV/65269705:_____/22:00076298 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/22:00128097

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.26692" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.26692</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ajh.26692" target="_blank" >10.1002/ajh.26692</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

  • Original language description

    The phase 3 VIALE-A study (NCT02993523) of venetoclax (Ven) + azacitidine (Aza) demonstrated significantly improved median overall survival (OS; 14.7 months) compared with placebo (Pbo) + Aza in patients with newly diagnosed acute myeloid leukemia (AML) who were aged GREATER-THAN OR EQUAL TO75 years or ineligible for intensive chemotherapy.1 The study protocol recommended dosing schedule modification following remission to mitigate hematologic adverse events (AEs; Figure 1A); these occurred in 83% of patients in the Ven + Aza arm. This post hoc analysis of VIALE-A evaluated the frequency and management of postremission cytopenia events, Ven exposure-response relationship with postremission cytopenias, and outcomes when dosing schedule modifications were required for grade 4 cytopenias.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    American Journal of Hematology

  • ISSN

    0361-8609

  • e-ISSN

    1096-8652

  • Volume of the periodical

    97

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    4

  • Pages from-to

    "E416"-"E419"

  • UT code for WoS article

    000854058000001

  • EID of the result in the Scopus database

    2-s2.0-85137974335